Key growth factors for the IORT market include an increased need for precise and targeted cancer treatments, rapid technological advancements that enhance treatment efficacy and safety, and supportive regulatory frameworks that allow for market expansion. Furthermore, the rising global incidence of cancer, along with efforts to reduce treatment periods and improve patient outcomes, is propelling the development of IORT as a feasible oncological therapy.
Interoperative radiation therapy (IORT) is a cancer treatment method that is usually used with surgery. It comprises providing a single, high-dose radiation therapy to a tumor site during surgery, just after the tumor has been removed. This is often performed with the use of a bespoke radiation delivery device. The advantage of IORT is that it allows for precise radiation targeting of the tumor bed while sparing healthy tissues surrounding it. Radiation given directly to the tumor site during surgery may help reduce the risk of cancer recurrence while limiting damage to other organs or tissues. IORT is used to treat a variety of cancers, including breast, colorectal, and pancreatic cancer. It’s often considered for cases where the tumour is located close to critical structures or organs, making it challenging to deliver radiation safely using conventional external beam radiation therapy.
Get a free Sample Report: https://meditechinsights.com/intraoperative-radiation-therapy-market/request-sample/
Efficiency and Efficacy: Driving Growth in Intraoperative Radiation Therapy.
Intraoperative radiation therapy (IORT) is a pioneering technology that is transforming cancer treatment. This particular method delivers a focused radiation dosage precisely to cancer areas during surgery, assuring pinpoint precision while preserving healthy tissues from radiation exposure. IORT market is expected to develop significantly due to a number of compelling factors. IORT’s ability to precisely target cancer cells during surgery is game-changing. It meets a fundamental demand for safer, more effective cancer therapies by reducing collateral harm to adjacent healthy tissues. This dramatic reduction in treatment time not only enhances patient convenience but also streamlines healthcare resource utilization. Preservation of healthy tissues is paramount in cancer treatment, particularly when tumours are in proximity to vital organs. IORT’s precise targeting minimizes the risk of damage to critical structures, improving patient outcomes and quality of life. Emerging evidence suggests that delivering radiation directly to the tumor bed during surgery may bolster treatment effectiveness, notably in preventing local recurrence. This potential enhancement in therapeutic outcomes positions IORT as a compelling option for clinicians and patients alike.
IORT: Transformative Trends and Growth Opportunities in Cancer Therapy
Intraoperative radiation therapy (IORT) is more than simply a new technology; it is a growing trend that is changing cancer treatment paradigms. As this novel technique gets traction, it opens up a plethora of enticing prospects that have the potential to alter the oncology landscape. It works flawlessly with minimally invasive surgical approaches to improve patient recovery and quality of life. Technological breakthroughs in radiation delivery systems and imaging technologies have accelerated the progress of IORT, increasing its usefulness across a wide range of cancer types. The rising adoption of IORT as the standard of therapy in some cancer types creates enormous revenue prospects. As awareness grows and more healthcare institutions implement IORT technology, the market is expected to expand rapidly. For instance,
- In January 2023, IntraOp Medical Corporation disclosed that physicians at Vanderbilt University Medical Center (VUMC) utilized the IntraOp Mobetron Intra-Operative Radiation Therapy to treat a pancreatic cancer patient, marking the first successful application of this treatment approach
While the upfront investment in IORT technology may be substantial, its long-term cost-effectiveness is a driving factor. By streamlining treatment processes, reducing hospitalization times, and potentially lowering the risk of complications, IORT offers significant cost savings for healthcare systems and payers. Clinical data supporting the efficacy of IORT in preventing local recurrence and improving survival outcomes present compelling opportunities for clinicians and healthcare providers. As evidence continues to accumulate, IORT’s role in achieving superior clinical outcomes will drive its adoption and integration into standard cancer treatment protocol. For instance,
- In August 2021, iCAD revealed promising findings from a two-center study showing that patients treated with the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for recurrent glioblastoma (GBM) lived without recurrence for 4 to 54 months post-treatment, contrasting with the control group who experienced recurrence within 2 to 10 months and survived for 2 to 22.5 months after treatment, as presented at the American Association of Neurological Surgeons (AANS) 2021 annual scientific meeting
- In August 2020, the publication of long-term results from the international TARGIT-A breast cancer study, utilizing ZEISS technology, affirmed the non-inferiority of targeted intra-operative radiotherapy (TARGIT) administered with ZEISS INTRABEAM immediately following tumour removal compared to external beam radiotherapy (EBRT), with similar risks of local tumour recurrence in the breast and reduced non-breast cancer mortality
To know more about the research report, fill out a quick inquiry for a sample report:
https://meditechinsights.com/intraoperative-radiation-therapy-market/
Global Perspectives: Regional Dynamics and Market Trends in IORT
North America dominates the worldwide IORT market, owing to improved healthcare infrastructure, high adoption rates of breakthrough medical technologies, and advantageous reimbursement policies. The area leads in technical breakthroughs in IORT systems, with ongoing research and development projects focused at improving treatment accuracy and patient outcomes. Europe is seeing increased acceptance of IORT technology, with established healthcare systems enabling extensive access to modern cancer therapies, including IORT. Europe is a clinical research hotspot in oncology, with multiple academic institutions and research institutes performing trials to assess the efficacy and cost-effectiveness of IORT in various cancer types. The existence of the European Medicines Agency (EMA) promotes regulatory harmonization among EU member states, expediting the clearance process for IORT technologies and driving market growth. The Asia-Pacific area is the fastest-growing market for IORT, driven by rising cancer rates, rising healthcare costs, and more knowledge of sophisticated treatment alternatives. Countries such as China, India, and Japan are leading the market development, with investments in healthcare infrastructure and a thriving medical tourism industry boosting demand for new cancer therapies such as IORT.
Competitive Landscape Analysis of the IORT Market
Prominent players in the intraoperative radiation therapy market include ZEISS
Group, iCAD, Inc., Eckert & Ziegler SE, Elekta Instrument AB, GMV INNOVATING SOLUTIONS PRIVATE LIMITED, Sensus Healthcare, Inc., IntraOp Medical Corporation Medical, Inc., Isoray, Inc., Becton, Dickinson and Company, Sordina IORT Technologies, Varian Medical Systems, Inc., and Theragenics Corporation
Organic and Inorganic Growth Strategies Adopted by Players to Establish Their Foothold in the Market
Players operating in this market are adopting both organic and inorganic growth strategies such as collaborations, and acquisitions to garner market share. For instance,
- In April 2020, Elekta introduced Geneva, the first universal gynaecological applicator for brachytherapy, developed using Elekta’s “outside-in” methodology and tailored to meet frontline cancer therapy requirements. Geneva has a simple assembly with only four clicks, making it the preferred choice for gynaecological brachytherapy across all cancer centers, improving accuracy for the primary treatment in 75% of cervical cancer cases.
- In April 2019, Sensus Healthcare, Inc. has partnered with the Perelman School of Medicine at the University of Pennsylvania’s radiation oncology department to conduct clinical research and development for Sensus’ Sculptura™ robotic intraoperative radiation therapy system.
The IORT Market is predicted to expand in the next years due to possible benefits such as precision targeting, time efficiency, therapeutic efficacy, technical improvements, strategic alliances, and aggressive organic and inorganic growth strategies used by the players.Sources: Medi-Tech Insights Analysis, Expert Interviews
Related:
Radioligand Therapy (RLT) Market: A ‘Game Changer’ for Cancer Treatment
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have successfully completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
